Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...

Wegovy's launch in Thaliand comes nearly a month after Eli Lilly launched its obesity management drug Mounjaro in India at ...

The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo ...

The CEO of Novo Holdings has warned that his $160 billion fund will slow down investment activity until the dust settles ...

COVID-19 in children and adolescents is associated with adverse long-term kidney outcomes, such as chronic kidney disease (CKD).

HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

In recent years our traditional understanding of both macrophages and neutrophils has been greatly challenged. Previously thought to promote inflammatory ...

Novo Nordisk has launched its popular weight-loss drug Wegovy in Thailand, marking its first entry into the Southeast Asian ...

Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's ...

Their own mini-boom of recent years has been largely fueled by one firm, Ozempic maker Novo Nordisk A/S, whose diabetes and ...

President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare should cover them.

Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...